within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FG02_Ramucirumab;

model Ramucirumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FG02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FG02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ramucirumab is a fully human IgG1 monoclonal antibody that targets the vascular endothelial growth factor receptor-2 (VEGFR-2), inhibiting angiogenesis. It is used and approved for the treatment of various advanced cancers, including gastric cancer, non-small cell lung cancer, and colorectal cancer, most often in combination with other chemotherapeutic agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients, both sexes, after intravenous infusion as monotherapy or in combination. Parameters are population pharmacokinetics from clinical trials in cancer populations.</p><h4>References</h4><ol><li><p>O&#x27;Brien, L, et al., &amp; Heathman, M (2017). Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. <i>British journal of clinical pharmacology</i> 83(12) 2741–2751. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13403&quot;>10.1111/bcp.13403</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28833321/&quot;>https://pubmed.ncbi.nlm.nih.gov/28833321</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=&quot;https://doi.org/10.4161/19420862.2015.988944&quot;>10.4161/19420862.2015.988944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25484055/&quot;>https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li><li><p>Greig, SL, &amp; Keating, GM (2015). Ramucirumab: A Review in Advanced Gastric Cancer. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 29(5) 341–351. DOI:<a href=&quot;https://doi.org/10.1007/s40259-015-0138-1&quot;>10.1007/s40259-015-0138-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26341713/&quot;>https://pubmed.ncbi.nlm.nih.gov/26341713</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ramucirumab;
